NWT funds cystic fibrosis drug Trikafta
Effective this week, the NWT is providing coverage for Trikafta, a life changing treatment for 90 per cent of Canadians with cystic fibrosis. Trikafta can be prescribed for residents 12 years and older who have a specific cystic fibrosis mutation.
Residents with cystic fibrosis being prescribed Trikafta can apply for coverage under the Government of the Northwest Territories’ (GNWT) Extended and Métis Health Benefits programs. First Nations and Inuit residents can apply under the Federal NIHB program. The estimated retail price is approximately $300,000 per patient per year.